MEI Pharma, Inc. (MEIP)
Stock Price Chart
Key Info
| Market Cap | 339.82M |
| Revenue (ttm) | 31.59M |
| Net Income (ttm) | -45.11M |
| Shares Out | 112.52M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 27 |
| Last Price | $3.02 |
| Previous Close | $2.90 |
| Change ($) | 0.12 |
| Change (%) | 4.14% |
| Day's Open | 2.93 |
| Day's Range | 2.93 - 3.03 |
| Day's Volume | 485,027 |
| 52-Week Range | 0.72 - 4.46 |
More Stats
| Market Cap | 339.82M |
| Enterprise Value | 172.36M |
| Earnings Date (est) | Feb 11, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 112.52M |
| Float | 99.97M |
| EPS (basic) | -0.51 |
| EPS (diluted) | -0.58 |
| FCF / Share | 0.34 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 11.09% |
| Payout Ratio | n/a |
| Shares Short | 7.73M |
| Short Ratio | 13.14 |
| Short % of Float | 7.73% |
| Beta | 1.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | 9.02 |
| PS Ratio | 10.76 |
| PB Ratio | 3.87 |
| Revenue | 31.59M |
| Operating Income | -27.50M |
| Net Income | -45.11M |
| Free Cash Flow | 37.69M |
| Net Cash | 167.46M |
| Net Cash / Share | 1.49 |
| Gross Margin | 83.07% |
| Operating Margin | -87.06% |
| Profit Margin | -142.80% |
| FCF Margin | 119.30% |
| ROA | -12.15% |
| ROE | -69.62% |
| ROIC | -3,443.70% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.91 | 4.92 | 1.62 | 23.25 | - | - | - | - | - | - |
| Revenue Growth | 488.26% | 203.02% | -93.02% | - | - | - | - | - | - | - |
| Gross Profit | 26.24 | 0.65 | -1.76 | 18.25 | - | - | - | - | - | - |
| Operating Income | -24.54 | -46.25 | -28.59 | 2.38 | -21.00 | -32.77 | -27.23 | -11.22 | -8.39 | -6.45 |
| Net Income | -46.02 | -16.82 | -40.07 | 2.67 | -20.86 | -32.69 | -27.15 | -11.19 | -7.52 | -6.78 |
| Shares Outstanding | 91.08 | 71.14 | 41.43 | 36.81 | 34.40 | 28.20 | 20.06 | 10.16 | 2.25 | 1.27 |
| Earnings Per Share | -0.51 | -0.75 | -0.97 | 0.07 | -0.61 | -1.16 | -1.35 | -1.10 | -3.35 | -5.34 |
| Operating Cash Flow | 34.26 | -29.42 | -21.04 | 3.49 | -17.86 | -28.07 | -19.45 | -10.04 | -7.08 | -6.50 |
| Capital Expenditures | -0.89 | -0.22 | - | -0.05 | - | -0.02 | -0.05 | -0.04 | - | -0.05 |
| Free Cash Flow | 33.36 | -29.64 | -21.04 | 3.44 | -17.86 | -28.08 | -19.50 | -10.08 | -7.08 | -6.55 |
| Cash & Equivalents | 183 | 74.49 | 103 | 53.57 | 45.92 | 63.78 | 48.79 | 35.57 | 6.20 | 3.86 |
| Net Cash / Debt | 183 | 74.49 | 103 | 53.57 | 45.92 | 63.78 | 48.79 | 35.57 | 6.20 | 3.86 |
| Assets | 210 | 82.66 | 105 | 55.70 | 47.16 | 64.75 | 49.81 | 36.55 | 6.37 | 4.17 |
| Liabilities | 132 | 34.73 | 54.20 | 4.87 | 5.51 | 4.96 | 4.62 | 1.68 | 1.77 | 2.37 |
| Book Value | 78.22 | 47.93 | 50.46 | 50.84 | 41.65 | 59.79 | 45.19 | 34.87 | 4.60 | 1.79 |
Company Profile
Company Details
| Full Name | MEI Pharma, Inc. |
| Country | United States |
| Employees | 51 |
| CEO | Daniel P. Gold |
Stock Information
| Ticker Symbol | MEIP |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: MEIP |
| IPO Date | December 19, 2003 |
Description
MEI Pharma, a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.